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Abstract
Background: Recent evidence suggests that the lipid-lowering agent atorvastatin is also a potent immunomodulator. The
aim of this study was to investigate the possible effect of atorvastatin on the decline of residual beta cell function in recent-
onset type 1 diabetes.
Methods and Findings: The randomised placebo-controlled Diabetes and Atorvastatin (DIATOR) Trial included 89 patients
with newly diagnosed type 1 diabetes and islet autoantibodies (mean age 30 years, 40% females), in 12 centres in Germany.
Patients received placebo or 80 mg/d atorvastatin for 18 months. As primary outcome stimulated serum C-peptide levels
were determined 90 min after a standardized liquid mixed meal. An intent-to-treat analysis was performed. Fasting and
stimulated C-peptide levels were not significantly different between groups at 18 months. However, median fasting serum
C-peptide levels dropped from baseline to 12 and 18 months in the placebo group (from 0. 34 to 0.23 and 0.20 nmol/l,
p,0.001) versus a nonsignificant decline in the atorvastatin group (from 0.34 to 0.27 and 0.30 nmol/l, ns). Median
stimulated C-peptide concentrations declined between baseline and 12 months (placebo from 0.89 to 0.71 nmol/l,
atorvastatin from 0.88 to 0.73 nmol/l, p,0.01 each) followed by a major loss by month 18 in the placebo group (to
0.48 nmol/l, p=0.047) but not in the atorvastatin group (to 0.71 nmol/l, ns). Median levels of total cholesterol and C-
reactive protein decreased in the atorvastatin group only (p,0.001 and p=0.04). Metabolic control was similar between
groups.
Conclusions: Atorvastatin treatment did not significantly preserve beta cell function although there may have been a
slower decline of beta-cell function which merits further study.
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Introduction
Immunosuppressive treatment of recent onset type 1 diabetes
has been shown to slow the decline of residual beta cell function
[1]. Recent trials which reported a delay in disease progression
include autologous stem cell therapy, treatment with immuno-
modulatory monoclonal antibodies or vaccination with disease-
associated autoantigens (see ref.2). The latter approach did not
cause recognizable treatment-related adverse effects. Statins have
been considered as immunomodulary agents because of their
ability to suppress the expression of adhesion molecules and MHC
class II molecules as well as of inflammatory mediators such as C-
reactive protein [3,4]. The inhibition of T-cell activation involves
the blockade of the interaction between T-lymphocytes and
antigen presenting cells by binding to an adhesion molecule
involved in this process, LFA-1 [5]. Soluble forms of ICAM-1 –
the natural receptor of LFA-1- were found to be decreased in
recent onset type 1 diabetic patients [6] and to inhibit type 1
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17554diabetes specific autoantigen T-cell proliferation [7]. Furthermore,
administration of recombinant forms of soluble ICAM-1 was
effective in inhibiting insulitis and diabetes-development in NOD
mice [8].
Atorvastatin showed beneficial effects in patients with rheuma-
toid arthritis [9], and in relapsing-remitting multiple sclerosis [10].
Another trial reported an increase of disease activity for the
combination of atorvastatin with interferon-b [11] whereas one
subsequent trial did not find such an adverse effect [12]. A third
trial reported better outcomes for the combination of atorvastatin
with interferon-b [13].
The possible beneficial effect of statin therapy on the beta cell
destructive process in pancreatic islets has been analysed in animal
models, with inconsistent results. In the multiple low-dose strepto-
zotocin models in CD-1 mice, administration of simvastatin delayed
or protected from the development of insulin-deficient diabetes [14],
whereas no effect was seen with atorvastatin treatment in C57BL/6
mice [15]. Statin treatment lowered the incidence of diabetes in the
autoimmune diabetic NOD mouse model in one out of three studies
[15–17] Treatment with simvastatin prolonged survival of islets
transplanted to NOD mice [14,18].
In view of the disease modifying activity of statins in two human
immune-mediated diseases we initiated the DIATOR (Diabetes
and Atorvastatin) Trial investigating the effects of treatment with
atorvastatin in the course of recent-onset type 1 diabetes.
Results
During the years 2004–2006 eighty-nine of the 105 patients
with recent-onset type 1 diabetes screened were identified as
eligible. Despite an extension of the recruitment period and of the
number of participating centers the goal of 160 patients was not
reached. The decision to stop screening was made by the Study
Committee based on the low recruitment rate of the last 12
months, while still being blinded for patient allocation to treatment
groups. After randomization two patients in the placebo group
were excluded because of not having met the inclusion criteria of
at least one islet autoantibody, leaving 87 patients for the intent-to-
treat analysis. In total, 78% of patients completed the visit at 12
months and 72% the final visit at 18 months (Fig. 1).
Baseline Characteristics
The two study groups were comparable with respect to baseline
parameters (Table 1). There also were no significant differences
between study centers, or between patients completing the full
study and drop-outs at different time points, with the exception of
higher baseline insulin dose in drop-outs vs. completers (not
shown).
Main Outcomes
Median fasting and stimulated C-peptide concentrations did not
differ significantly between atorvastatin and placebo at 18 months
(0.30 vs. 0.20 nmol/l, p=0.40, and 0.71 vs. 0.48 nmol/l, p=0.36,
respectively) although there was a 50% difference for fasting and a
48% difference for stimulated C-peptide. The course of C-peptide
secretion over the study period is depicted in Fig. 2. Median fasting
serum C-peptide levels dropped from baseline to 12 and 18 months
in the placebo group (from 0. 34 to 0.23 and 0.20 nmol/l, p,0.001)
whereastheyremainedstableinthe atorvastatingroup(from0.34to
0.27 and 0.30 nmol/l, ns) (Fig. 2A). Mixed-meal stimulated beta
cell secretion initially decreased in both groups until 12 months
(from 0.89 to 0.71 nmol/l in the placebo group, from 0.88 to
0.73 nmol/l in the atoravastatin group, p,0.01 for both) with no
further deterioration until 18 months in the atorvastatin group
(0.71 nmol/l), whereas there was significant further loss of beta cell
function in the placebo group (0.48 nmol/l, p,0.046, Fig. 2B).
Additional exploratory analyses were performed to search for a
treatment effect in subgroups defined by center allocation, high vs.
low age, BMI or baseline levels of fasting or stimulated C-peptide,
number of islet autoantibodies. No significant difference for the
primary endpoint at 18 months was found.
Efficacy of Atorvastatin Treatment
In the atorvastatin group median baseline concentrations of
total cholesterol (4.04 mmol/l), LDL-cholesterol (2.51 mmol/l)
and triglyceride (0.75 mmol/l) decreased by 3 months and
remained at low levels throughout the treatment period (Fig. 3).
From baseline to 18 months decreases were 32.2% for total, 52.3%
for LDL-cholesterol, and 26.0% for triglyceride concentrations.
(p,0.001, each). Median HDL-cholesterol levels increased from
1.05 mmol/l at baseline to 1.22 mmol/l at 18 months (p,0.001).
In the placebo group, there were no significant changes
throughout the treatment period.
Changes in immune parameters were determined by comparing
serum concentrations at baseline and 3 months. Median plasma
CRP concentrations decreased slightly in the atorvastatin (from
0.95 (IQR 2.01) to 0.73 mg/l (1.03), p=0.03, but not in the
placebo group (from 0.88 (1.59) to 0.78 mg/l (1.31)). No
significant changes were observed in either group for median
plasma concentrations of the soluble adhesion molecules sICAM-1
and E-selectin, or serum concentrations of cytokines IFNc, IL-6,
IL-18 cytokine antagonist IL-1ra, chemokines eotaxin, IP-10,
MCP-4, MIP-1b, MDC, IL-8 and TARC (data not shown).
Median concentrations of MCP-1 decreased significantly in the
placebo group (from 431 to 356 pg/ml, p=0.009) but not in the
atorvastatin group (from 367 to 303 pg/ml, ns).). The only
difference between groups was a 11% higher concentration of IL-
1ra at 3 months with atorvastatin treatment (p=0.02).
Metabolic Control
Mean HbA1c levels decreased from baseline to 6 months in
both study groups (from 7.8 to 6.6% with atorvastatin, from 7.5 to
6.7% with placebo, both p,0.001) and stayed at a lower level
throughout the treatment period in the atorvastatin group (6.8% at
18 months), while under placebo treatment mean values increased
and were no more different from baseline at 18 months (7.1%,
p.0.05) (Fig. 4A). However, differences between treatment
groups were not significant at either 12 or 18 months. Mean
daily insulin dose increased in the atorvastatin group from
0.32 IU/kg at baseline to 0.48 IU/kg at 18 months, and in the
placebo group from 0.33 to 0.44 IU/kg (both p,0.001). The rise
in insulin dose was more rapid in the atorvastatin group, resulting
in a higher dose at 12 months compared to the placebo group,
p=0.007 (Fig. 4B).
Safety Results
Dose reductions (from 80 mg/d to 40 mg/d) due to adverse
effects occurred for 1–1.7 years in 3 cases: 1 case of myalgia and
myopathia (atorvastatin), 1 of arthralgia (placebo) and 1 of
increased CPK serum levels (atorvastatin). Medication was
temporarily discontinued in 7 cases because of symptoms lasting
between 1 and 28 days (atorvastatin: Helicobacter infection,
bilious colic in patient with gallstone predisposition, swollen lids
with headache, back pain after moving into a new domicile,
respiratory infection with fever; placebo: muscle pain, blood in
stool) Permanent discontinuation of atorvastatin occurred in three
persons, after temporary treatment halt because of intestinal
cramps, because of mildly elevated hepatic enzyme levels or
Atorvastatin in Type 1 Diabetes
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17554because of neurological symptoms. In the atorvastatin group, 18
patients (39.1%) reported 64 adverse events vs. 15 patients (34.9%)
with 31 adverse events in the placebo group. In the atorvastatin
group 9 of the 64 adverse events in 7 patients were rated as
‘‘possibly’’ or ‘‘probably’’ related to medication, vs. 4 of the 28
adverse events in 4 placebo patients (difference not significant).
Five events in 4 patients of the atorvastatin group and 3 events in 3
patients of the placebo group were classified as severe adverse
events; none was classified as ‘‘possibly’’ or ‘‘probably’’ related to
medication. All patients recovered or were stabilized. CPK levels
were elevated in 16 patients of the atorvastatin and in 6 patients of
the placebo group. However, in most cases these elevations were of
mild character (maximum 405 U/l in the atorvastatin vs. 321 U/l
in the placebo group) and critical serum levels of .10 times of the
upper normal range (i.e. .2000 U/l) were never observed.
Discussion
The trial did not find a significant effect of atorvastatin
treatment with regard to the primary endpoint, i.e. the comparison
of stimulated C-peptide concentrations between groups at 18
months. Also, the two groups did not differ significantly with
regard to fasting C-peptide levels. In both cases, median C-peptide
concentrations were around 50% higher in the atorvastatin than
Figure 1. Study flow diagram. Patients were screened in 12 participating centers by using the inclusion and exclusion criteria.
doi:10.1371/journal.pone.0017554.g001
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significant because of an unexpectedly large range or standard
deviation of C-peptide concentrations measured, in both groups.
In this regard, a major limitation of the trial is that the actual
number of patients recruited was lower than foreseen in the study
protocol (total 89 vs. 160).
As secondary analysis we compared median C-peptide concen-
trations over the study period within a group. There was a
significant deterioration of residual beta cell function in the
placebo group but not the atorvastatin group. In the placebo
group, median fasting C-peptide concentrations decreased from
baseline by 32% at 12 months and by 41% at 18 months
(p,0.001), whereas there was no significant change in the
atorvastatin group. Median stimulated C-peptide concentrations
decreased mildly in both groups by 12 months (by 20% in the
placebo group and by 17% in the atorvastatin group, p,0.01
each). At 18 months median C-peptide concentrations had further
decreased (p=0.046), total decrease by 46% of baseline, whereas
there was no further deterioration in the atorvastatin group, total
decrease by 19%.
These differences were not reflected by lower insulin doses in
the atorvastatin group. Rather, there was a more rapid increase of
insulin dosing leading to significantly higher insulin doses at 12
months although not at 18 months. Some types of statins have
been reported to increase or decrease insulin resistance but a
consistent effect was not noted for atorvastatin in a recent meta-
analysis [19]. Partial preservation of residual beta cell function is
considered as clinically relevant goal also in the absence of lower
insulin requirements, because of a lower risk of complications
[20,21].
Since beta cell function is affected by the concentration of
glucose at the start of the test, the study protocol requested that no
mixed meal test should be performed if fasting blood glucose was
outside 4–11 mmol/l. However, even in this concentration range,
ambient glucose may affect the outcome of beta cell function tests,
as suggest by the recent international workshop comparing the
liquid mixed meal with the glucagon assay [22]. There was an
inverse relationship between fasting blood glucose and subsequent
peak C-peptide concentrations following the liquid mixed meal.
This means that the higher HbA1c levels (and consequently higher
mean fasting blood glucose levels) in the atorvastatin group at 12
and 18 months probably has led to a lower C-peptide response,
and hence has downsized the difference between the two groups.
Unfortunately, there is no algorithm or formula for adjusting C-
peptide responses for ambient glucose.
As expected, regular intake of atorvastatin caused a decrease of
total and LDL-cholesterol levels in serum, a decrease of
triglyceride levels and a small increase of HDL-cholesterol levels.
Median concentrations of CRP were low at baseline, but were
further lowered by statin treatment. All of these effects are
consequences of inhibiting the synthesis of mevalonate from acetyl
coenzyme A by hydroxyl-3-methylglutaryl-coenzyme A reductase.
This is a rate limiting step in cholesterol synthesis, and the
mevalonate pathway gives rise to a number of compounds such as
farnesyl or geranylgeranyl pyrophosphate which can modify
several transcription factors controlling cell growth, endothelial
activity and immune gene expression [3,23–26]. The amelioration
of the lipid status by atorvastatin treatment may be considered
advantageous, independent of the slowed loss of beta cell function.
The decrease in systemic CRP levels may indicate a dampening of
inflammatory processes, although our analysis of circulating
concentrations of 14 different immune mediators, including
soluble adhesion molecules, cytokines, a cytokine antagonist and
chemokines did not reveal statin-treatment associated changes.
Table 1. Baseline characteristics.
Characteristic Atorvastatin Group Placebo Group
Mean age (SD), y 30.0 (6.8) 29.8 (6.5)
Men, n (%) 26 (57 27 (63)
Mean BMI (kg/m
2) (SD) 23.4 (3.1) 24.2 (3.0)
Mean HbA1c (%) (SD) 7.8 (1.8) 7.5 (1.6)
Mean insulin dose (IU/kg) (SD) 0.32 (0.18) 0.33 (0.19)
Median fasting C-peptide (nmol/l)(IQR) 0.34 (0.22) 0.34 (0.20)
Median stim. C-peptide (nmol/l)(IQR)
a 0.88 (0.66) 0.89 (0.67)
GAD65 autoantibodies
b:
patients positive (n) 42 40
median titer (U/ml) (IQR) 34 (63) 21 (46)
IA-2 autoantibodies
b:
patients positive (n) 25 25
median titer (U/ml) (IQR) 8.6 (16) 6.3 (13)
Islet cell antibodies
b
patients positive (n) 37 30
median titer (JDFU/ml) (IQR) 40 (0) 40 (0)
Patients positive for one autoantibody (n) 7 8
Patients positive for two autoantibodies (n) 14 12
Patients positive for three autoantibodies (n) 23 21
aStimulated serum C-peptide concentrations were determined 90 min after intake of a standardized liquid mixed meal.
bData on GAD, IA2 and islet cell antibodies were not available from 2, 6 and 4 persons, respectively.
doi:10.1371/journal.pone.0017554.t001
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but does not exclude that statin treatment affects islet-antigen
specific cellular immunity, e.g. through an increase of regulatory
T-cell functions in pancreatic islets or draining lymph nodes.
Indeed, statin blockade of the mevalonate pathway has been
observed to promote the generation of Foxp3 positive regulatory
T-cells in mice and a shift from autoaggressive Th1 to more
benign Th2 immunity [27–30]. Atorvastatin-induced Kru ¨ppel-like
factor 2 expression may be a critical event for these effects [31].
Besides the immunomodulatory properties atorvastatin may also
target pancreatic islets. A recent study in streptozotocin treated rat
pups reported an increase in the number of small islets following
atorvastatin treatment, suggestive of neogenesis. Since angiogen-
esis preceded the increase in beta cell mass, target of atorvastatin
may be the endothelium [32].
Atorvastatin was generally well tolerated. Dose reductions or
temporary discontinuation of treatment were reported in 8 cases,
in three cases treatment was permanently discontinued. Elevation
of CPK levels were observed more often in the atorvastatin than in
the placebo group (35 vs 14%) but did not reach critical levels of
.2000 U/l.
In summary, we report that treatment with atorvastatin over 18
months was safe and well tolerated in adult patients with recent-
onset type 1 diabetes. At 18 months, the atorvastatin group did not
exhibit significantly higher fasting or stimulated C-peptide
concentrations than the placebo group. Secondary analyses of
the course of C-peptide secretion within groups found some
preservation of fasting and stimulated serum C-peptide concen-
trations in the atorvastatin but not the placebo group. A
comparison with results from the ongoing trial of atorvastatin in
children and adolescents with type 1 diabetes (ClinicalTrials.gov
registration number NCT00529191) will help to judge the
potential of this treatment modality.
Figure 2. Course of C-peptide secretion in the study groups.
Fasting serum C-peptide concentrations (a) were the mean of two
blood samples obtained 5 min apart, samples for stimulated serum C-
peptide (b) were obtained 90 min after a standard liquid mixed meal.
Numbers in columns indicate the IQR. Filled bars, atorvastatin, empty
bars, placebo. Differences between groups were not significant.
Comparison between groups by Mann-Whitey-u-test, within groups
by Wilcoxon signed rank test.
doi:10.1371/journal.pone.0017554.g002
Figure 3. Effect of atorvastatin on blood lipid levels. Shown are
mean levels of total (black lines) and LDL-cholesterol (blue lines) (a),
HDL-cholesterol (black lines) and triglycerides (blue lines) (b), bars
indicate standard deviation, dotted lines depict placebo, continuous
lines atorvastatin. * p,0.05, ** p,0.01, *** p,0.001 for comparison
with baseline values. Only changes for the atorvastatin group are
significant.
doi:10.1371/journal.pone.0017554.g003
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Ethics statement
The study was conducted in accordance with the Declaration of
Helsinki, and approval by the ethics committees of the
A ¨rztekammer Nordrhein was obtained. All patients provided
written informed consent prior to study entry. The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1.
Study population
In participating centers throughout Germany (n=12), patients
with newly diagnosed type 1 diabetes were screened for eligibility.
In accordance with current guidelines this new treatment modality
was first tried in adult patients. Inclusion criteria were insulin
requiring diabetes for two weeks to 3 months, tested positive for at
least one islet autoantibody (to glutamic acid decarboxylase (GAD)
65, to insulinoma-associated antigen (IA)-2 or islet cell antibodies
(ICA)), age 18–39 years. Female patients were to use contraceptive
methods. Major exclusion criteria were concomitant other
diseases, use of anti-inflammatory, antihypertensive, lipid-lowering
or antidiabetic drugs other than insulin, a serum creatine
phosphokinase (CPK) level .5 times the upper limit of normal,
a serum LDL-cholesterol level .150 mg/dl or any other
conditions considered relevant by the investigator. All patients
were of Caucasian ethnicity.
Procedure
The study was a Phase I trial conducted as randomized, double-
blind, placebo-controlled, outpatient, parallel group study. Pa-
tients were assigned to treatment with either atorvastatin or
placebo for a period of 18 months in a one-to-one manner using a
computer-generated randomization list, with stratification for
participating centers. The starting atorvastatin dose was 40 mg/
d or a matching number of placebo tablets. After 4 weeks, the dose
was increased to 80 mg/d or matching placebo. Counts of unused
tablets were performed and did not indicate a lack of compliance,
defined by .20% of tablets returned on two consecutive visits.
During the study, the investigators were advised to reduce the dose
to 40 mg/d in case of side-effects (e.g. myalgia). Insulin treatment
was continued throughout the study with a recommended
treatment goal of HbA1c below 6.5% from 3 months on.
Follow-up and Outcome Measures
Patients attended visits at 0, 3, 6, 12 and 18 months, without
food intake for the preceding 10 hours. Primary outcome was
stimulated C-peptide secretion, assessed as serum C-peptide
concentrations after a standardised liquid mixed meal (Boost
HPH (Mead Johnson, Evansville, IN, USA), 6 ml per kg body
weight with a maximum of 360 ml) which was performed at
months 0, 12 and 18. Patients had to refrain from alcohol intake
and unaccustomed strenuous physical activity for 48 hours prior to
the test. In the morning, a capillary blood glucose measurement
was done and the test was performed if fasting blood glucose was
$4 mmol/l and #11.1 mmol/l. The test was performed in the
morning between 7 and 10 a.m. The patient should not have taken
any short-acting insulin at least 6 hours prior to the test. A first
blood sample was drawn five minutes, a second one immediately
before the liquid meal was taken in (mean value as formal ‘‘time
zero’’). The test meal had to be ingested within 5 minutes. Another
blood sample was drawn after 90 min, following the guideline of
the Diabetes Control and Complications Trial [33]. A recent
international workshop found a good correlation between
measuring C-peptide levels at this single time point versus
determining the area under the curve [22]. Primary outcome
measure was stimulated serum C-peptide levels at 12 or 18
months. Serum glucose, C-peptide (immunoenzymatic assay,
Biosource/Invitrogen, Karlsruhe, Germany), lipid and immune
parameters were analyzed in a central laboratory.
C-reactive protein (CRP) concentrations were determined by an
immunonephelometric assay [34], all other immune mediators
were measured by double-antibody ELISA (sICAM-1, E-selectin,
IL-6, IL-1ra, IFNc, eotaxin, IP-10, MCP-4, MIP-1b, MDC,
TARC) or bead-based multiplex technology (IL-18, MCP-1, IL-8)
[35]. GAD65 and IA-2 antibodies were determined by radioligand
binding assay (CentAK anti-GAD65, CentAK anti-IA-2, Medi-
pan, Berlin, Germany). ICA was determined by immunofluores-
cent staining on human AB- positive pancreatic sections as
described [36]. The immune laboratory participated in Standard-
Figure 4. Metabolic control during the study (HbA1c (a), insulin
dose (b). Filled bars, atorvastatin, empty bars, placebo. Bars indicate
standard deviation, for HbA1c p-values describe differences of mean
values from baseline determined by ANCOVA with correction for
baseline HbA1c and BMI (which correlated with later HbA1c levels),
**, p,0.01; ***, p,0.001. Mean insulin doses per kg bodyweight were
different between groups at 12 months (p=0.007, comparison of log-
transformed mean values by ANCOVA with correction for baseline
insulin dose and age (which correlated with later insulin doses).
doi:10.1371/journal.pone.0017554.g004
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Society with following results: GAD antibody sensitivity 0.72;
specificity 0.91; IA-2 antibody sensitivity 0.64, specificity 0.96.
Statistical Analysis
Based on data on C-peptide levels from patient files of the
German Diabetes Center it was calculated that for the primary
endpoint 80 patients per group would allow to recognize a 20%
difference between study groups in median stimulated serum C-
peptide levels at 18 months with a type 1 error of ,1%, power
95%. For the actual number of patients recruited, the p-value was
,0.05, power 80%. All patients who received at least one dose of
study treatment were included in the safety analysis. The statistical
evaluation (intent-to-treat analysis) was performed by using
validated software (SAS Version 9.2). Tests for normal distribu-
tion were performed by Kolmogorov-Smirnov. Values with
(log-)normal distribution are given as mean/SD, comparisons
between groups were made with unpaired t-test or ANOVA, or by
paired t-test within groups; F-test was used to check whether or not
variances were equal and appropriate tests were used: pooled
variance test if variances were equal, Satterthwaite test if variances
were unequal. Comparisons between groups included all patients,
for comparisons within a group only those patients could be
included where baseline and later data were available. Values
without normal distribution are given as median and interquartile
range (compared between groups with Mann-Whitney u-test,
within groups with Wilcoxon signed rank test) Dichotomous/
categorical variables are given as proportions (Fisher’s exact or
Chi-square test). Missing data were not substituted. Exploratory
analyses were performed for patient subgroups below or above
median age, BMI, stimulated or fasting C-peptide at baseline.
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